Cipla Share Price Falls Nearly 5% After USFDA Flags Compliance Issues at Key Partner

Cipla share price (NSE: CIPLA) extended its decline on Wednesday, January 7, falling nearly 5% after the US Food and Drug Administration (USFDA) released observations related to Pharmathen International, a key manufacturing partner of the company.

The stock was trading around ₹1,462.9, down about 4.5%, marking the lowest level of the day.

Why Cipla Share Price Fell?

Cipla has partnered with Pharmathen, a Greece-based contract manufacturing organisation, to commercialise the tumour drug Lanreotide in the US market. The regulatory action against Pharmathen has raised concerns among investors, leading to selling pressure on Cipla shares.

USFDA Observations on Pharmathen

According to the USFDA, several compliance gaps were identified at Pharmathen’s manufacturing facilities. These include:

• Weak procedures to prevent contamination
• Inadequate systems to maintain sterile conditions
• Deficiencies in aseptic processing areas
• Gaps in laboratory controls, including missing procedures
• Failure to follow approved sampling and testing processes
• Poor condition of manufacturing buildings

The regulator also flagged issues related to ensuring the purity and quality of drug products.

Also Read: Government Leans on Dividends as IDBI Bank Sale Becomes Key to FY26 Capital Receipts!

Cipla’s Recent Stock Performance

With today’s fall, Cipla shares are now down around 2.5% over the past 12 months, reflecting continued pressure on the stock amid regulatory and market concerns.

Conclusion

Cipla shares came under pressure after the USFDA highlighted multiple compliance issues at Pharmathen, its key manufacturing partner for Lanreotide in the US. While the long-term impact will depend on how quickly these issues are resolved and whether alternative arrangements are available, the regulatory development has weighed on near-term investor sentiment.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.